The American Society of Clinical Oncology (ASCO) has named adoptive cell immunotherapy as their clinical cancer Advance of the Year.
Browsing: Taxonomy > Personalized medicine
Discover the importance of DNA methylation changes in the identification of potential biomarkers relevant for clinical follow-up and personalized medicine of chronic lymphocytic leukemia.
How can ASCO’s CancerLinQ help us manage the vast amount of data required to provide high-quality cancer care?
In a first of its kind study, blood sample analysis detects genomic alterations that can predict which cancer patients should receive checkpoint inhibitor immunotherapy.
In this review article, the current knowledge of miRNAs and colorectal cancer diagnosis, prognosis and novel or evolving therapeutic concepts are discussed.
In this editorial from Future Science OA, discover the role that nanotechnology could play in driving personalized medicine for cancer forwards.
This article provides a immunotherapy perspective of Ipilimumab, a CTLA-4-targeted monoclonal antibody, reviewing drug mechanism, blockade, combination therapies and future prospectives.
Prospective clinical trial results demonstrate that a biomarker blood test could detect lung cancer recurrence on average 6 months earlier than CT scans.